New-Onset T1D Trials

Many immunotherapy clinical trials target individuals who have recently been diagnosed with type 1 diabetes, with goals to preserve their beta cell function and prevent disease progression. Find the list of clinical trials offered in the area along with contact information and links to more information.

GLADIATOR

A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with recent onset type 1 diabetes and a low residual B-cell function at baseline.

​Joslin Diabetes Center, Boston, MA
Clinical Trials Website


Recruiting

ITN DESIGNATE

A T cell phenotype signature driven dose finding study with siplizumab in type 1 diabetes mellitus
​Joslin Diabetes Center, Boston, MA
DESIGNATE Study Website


Recruiting

T1D RELAY

Rituximab-pvvr / Abatacept Newly Diagnosed Study

Naomi Berrie Diabetes Center, New York, NY
Yale University, New Haven, CT
T1D RELAY Trial Website

Recruiting

JAKPOT T1D

JAK Inhibitors Newly Diagnosed Study

Naomi Berrie Diabetes Center, New York, NY
Yale University, New Haven, CT
JAKPOT T1D Trial Website

Recruiting

  • The safety and scientific validity of a research study is the responsibility of the study investigators and the study sponsor.
  • It is important to evaluate the risks and potential benefits of clinical studies and to talk to your health care provider(s) before participating in a study.